| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human GMAP-210/TRIP11 recombinant protein (Position: Q1292-R1926) was used as the immunogen for the TRIP11 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
TRIP11 Antibody / Thyroid receptor-interacting protein 11 / GMAP-210 is a anti-TRIP11 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Rat.
Key elements and design rationale
- Target: TRIP11
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
TRIP11/GMAP-210 contains an N-terminal GRAB domain that interacts with the small GTPase ARF1 and a C-terminal acidic motif that binds to vesicular membranes. These dual binding regions enable the protein to bridge vesicles and the Golgi surface, stabilizing Golgi ribbon structure and promoting vesicle docking. In addition, its extended coiled-coil conformation provides a physical scaffold that organizes Golgi cisternae and positions them relative to the microtubule network. Depletion or mutation of GMAP-210 results in Golgi fragmentation, defective cargo trafficking, and impaired ciliary protein transport.
The TRIP11 antibody is widely used in cell biology, neurobiology, and developmental research to study Golgi morphology and vesicle tethering. Western blot analysis typically identifies a 210 kilodalton band corresponding to full-length GMAP-210, while immunofluorescence reveals Golgi-localized perinuclear staining. This antibody enables detailed visualization of Golgi organization, vesicle docking, and intracellular transport pathways.
Mutations in TRIP11 cause achondrogenesis type 1A, a lethal skeletal dysplasia resulting from defective protein secretion and ciliary dysfunction. Beyond skeletal disease, altered expression of GMAP-210 affects neural development, epithelial polarization, and secretion of extracellular matrix proteins. The TRIP11 antibody supports research into Golgi-associated transport, ciliogenesis, and protein trafficking disorders.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
